Revance Therapeutics reported $5.59M in Trade Debtors for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Trade Debtors Change
Aerie Pharmaceuticals AERI:US $ 68.08M 4.46M
ALKERMES ALKS:US 262.33M 7.83M
Bristol Myers Squibb BMY:US $ 12540M 4029M
Cara Therapeutics CARA:US $ 9.17M 5.54M
Coherus Biosciences CHRS:US $ 115.71M 1.33M
Eli Lilly And LLY:US $ 7672.4M 133.3M
Endo International Ordinary Shares ENDP:US $ 498.9M 13.24M
Horizon Pharma HZNP:US $ 673.31M 11.2M
JAZZ PHA JAZZ:US $ 594.03M 21.64M
Neurocrine Biosciences NBIX:US $ 279M 15.5M
Pacira Pharmaceuticals PCRX:US $ 91.1M 1M
Procter & Gamble PG:US $ 5143M 370M
Revance Therapeutics RVNC:US $ 5.59M 1.12M
Supernus Pharmaceuticals SUPN:US $ 158.06M 12.91M
Teva Pharmaceutical Industries TEVA:US $ 4471M 218M